J&J's Drugs Get CHMP Recommendations for Blood Cancer Indications

Key Takeaways JNJ's Darzalex gets CHMP nod to treat high-risk smoldering multiple myeloma in adults. Imbruvica also earns CHMP support for frontline mantle cell lymphoma use with chemo. Both decisions are backed by phase III studies showing significant survival improvements.J&J (JNJ) announced that the EMA’s Committee for Medicinal Products for Human Use (“CHMP”) recommended granting label expansion to its two key products, Darzalex and Imbruvica, across separate new indications.CHMP Endorses JNJ’s Darzal ...